The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
Top Cited Papers
Open Access
- 23 June 2016
- journal article
- Published by American Society of Hematology in Blood
- Vol. 127 (25), 3215-3224
- https://doi.org/10.1182/blood-2016-01-688796
Abstract
Key Points Venetoclax potently induces rapid onset apoptosis of CLL cells in vitro and in vivo, independently of TP53 function. Objective responses in patients with del(17p) and/or TP53-mutated CLL are as deep as patients with no perturbation of TP53.Keywords
This publication has 36 references indexed in Scilit:
- ABT‐199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not plateletsBritish Journal of Haematology, 2013
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- Targeting the B-Cell Lymphoma/Leukemia 2 Family in CancerJournal of Clinical Oncology, 2012
- Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic ChemotherapyScience, 2011
- A Unified Model of Mammalian BCL-2 Protein Family Interactions at the MitochondriaMolecular Cell, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Clearance of apoptotic cells: implications in health and diseaseThe Journal of cell biology, 2010
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737JCI Insight, 2007
- The Hallmarks of CancerCell, 2000